The US Food and Drug Administration (FDA) has concluded an unexpected visit to Solara's Puducherry facility, marking the end of the inspection with a Voluntary Action Indicated (VAI) status. Four issues were identified during the inspection but were swiftly addressed by Solara, leading to its resolution on April 24, 2026.

Vedanta is set to demerge, with shareholders receiving stocks of four new entities post an ex-date. Additionally, companies like RVNL, BHEL, OneSource, Wanbury, Solara, Adroit, Enviro, and MobiKwik are under scrutiny for potential deals, approvals, and inspections.

Solara Pharma has issued a final call notice for its rights shares at ₹112.5 per share, with the deadline for payment set on May 7, 2026. The price includes a face value of ₹3 and a premium of ₹109.5.